N-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)sulfamide | 1174169-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)sulfamide
• 英文别名: N-[1-(6,7-dimethoxy-4-quinazolinyl)-4-piperidinyl]sulfamide；6,7-dimethoxy-4-[4-(sulfamoylamino)piperidin-1-yl]quinazoline
• CAS: 1174169-97-1
• 化学式: C₁₅H₂₁N₅O₄S
• 分子量: 367.429
• InChiKey: LSGJEWTUUSFLAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  tert-butyl 4-(sulfamoylamino)piperidine-1-carboxylate 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 异丙醇 为溶剂， 反应 16.0h， 生成 N-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)sulfamide
  参考文献：
  名称：

  [EN] ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE-PHOSPHODIESTÉRASE (ENPP-1) ET UTILISATIONS DE CES DERNIERS

  摘要：

  本文揭示了一种增强和促进体内I型干扰素产生的方法和化合物。在某些实施例中，本文所披露的化合物是ENPP-1抑制剂，药物组合物，以及用于治疗癌症或病毒感染的方法。

  公开号：

  WO2019046778A1

文献信息

• [EN] QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE QUINOLÉINE ET DE QUINAZOLINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：STINGRAY THERAPEUTICS INC

  公开号：WO2020190912A1

  公开（公告）日：2020-09-24

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

  化合物及其制备和用作治疗或预防剂的方法，例如通过靶向Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。
• Quinoline and quinazoline compounds and methods of use thereof
  申请人：Stingray Therapeutics, Inc.

  公开号：US11407729B2

  公开（公告）日：2022-08-09

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

  化合物及其制备和用作治疗剂或预防剂的方法，例如通过靶向八核苷酸焦磷酸酶/磷酸二酯酶-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。
• Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: Alleviating hERG interactions through structure based design
  作者：Snahel D. Patel、Wendy M. Habeski、Alan C. Cheng、Elisa de la Cruz、Christine Loh、Natasha M. Kablaoui

  DOI：10.1016/j.bmcl.2009.04.006

  日期：2009.6

  PC-1 (NPP-1) inhibitors may be useful as therapeutics for the treatment of CDDP (calcium pyrophosphate dehydrate) deposition disease and osteoarthritis. We have identified a series of potent quinazolin-4-piperidin-4-ethyl sulfamide PC-1 inhibitors. The series, however, suffers from high affinity binding to hERG potassium channels, which can cause drug-induced QT prolongation. We used a hERG homology model to identify potential key interactions between our compounds and hERG, and the information gained was used to design and prepare a series of quinazolin-4-piperidin-4-methyl sulfamides that retain PC-1 activity but lack binding affinity for hERG. (C) 2009 Elsevier Ltd. All rights reserved.
• ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF
  申请人：AbbVie Inc.

  公开号：EP3676254A1

  公开（公告）日：2020-07-08
• QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Stingray Therapeutics, Inc.

  公开号：US20200299258A1

  公开（公告）日：2020-09-24

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).